These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12751712)

  • 1. Safety and efficacy of molgramostim as an adjunctive therapy in critically ill patients with severe sepsis.
    Myrianthefs PM; Karabatsos EG; Karatzas SP; Boutzouka EG; Venetsanou KF; Evagelopoulou PL; Fildissis GA; Legakis NJ; Baltopoulos GJ
    Scand J Infect Dis; 2003; 35(3):175-9. PubMed ID: 12751712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The organ protective effects and timing of continuous blood purification in the treatment of severe sepsis：a double-blind randomized controlled trial].
    Zhou R; Weng F; Dai W; Yan J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2016 Mar; 28(3):241-5. PubMed ID: 29917338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of etomidate in severe sepsis and septic shock.
    Dmello D; Taylor S; O'Brien J; Matuschak GM
    Chest; 2010 Dec; 138(6):1327-32. PubMed ID: 20651024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of early use of neuromuscular blocking agents in patients with severe sepsis and acute respiratory distress syndrome].
    Lyu G; Wang X; Jiang W; Cai T; Zhang Y
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 May; 26(5):325-9. PubMed ID: 24809261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortality.
    Presneill JJ; Waring PM; Layton JE; Maher DW; Cebon J; Harley NS; Wilson JW; Cade JF
    Crit Care Med; 2000 Jul; 28(7):2344-54. PubMed ID: 10921563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma kallistatin in critically ill patients with severe sepsis and septic shock.
    Lin WC; Chen CW; Chao L; Chao J; Lin YS
    PLoS One; 2017; 12(5):e0178387. PubMed ID: 28542440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential organ failure assessment score as the determinant of outcome for patients with severe sepsis.
    Vosylius S; Sipylaite J; Ivaskevicius J
    Croat Med J; 2004 Dec; 45(6):715-20. PubMed ID: 15578805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of lornoxicam on the physiology of severe sepsis.
    Memiş D; Karamanlioğlu B; Turan A; Koyuncu O; Pamukçu Z
    Crit Care; 2004 Dec; 8(6):R474-82. PubMed ID: 15566594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. sTREM-1 predicts intensive care unit and 28-day mortality in cancer patients with severe sepsis and septic shock.
    Ravetti CG; Moura AD; Vieira ÉL; Pedroso ÊR; Teixeira AL
    J Crit Care; 2015 Apr; 30(2):440.e7-13. PubMed ID: 25541104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination of Weighted index of comorbidities and sepsis-related organ failure assessment score in death risk evaluation of septic patients].
    Cui Y; Li Y; Zhang S; Li H; Chen D; Lin Z; Tian Z
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Jan; 26(1):41-5. PubMed ID: 24649524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of low serum vitamin D for infection risk, disease severity and mortality in critically ill patients.
    Su LX; Jiang ZX; Cao LC; Xiao K; Song JP; Li H; Zhang X; Yan P; Feng D; Liu CT; Li X; Xie LX
    Chin Med J (Engl); 2013 Jul; 126(14):2725-30. PubMed ID: 23876904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial.
    Orozco H; Arch J; Medina-Franco H; Pantoja JP; González QH; Vilatoba M; Hinojosa C; Vargas-Vorackova F; Sifuentes-Osornio J
    Arch Surg; 2006 Feb; 141(2):150-3; discussion 154. PubMed ID: 16490891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
    Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
    Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation of intestinal fatty acid binding protein and intestinal injury in severe sepsis].
    Zhu C; Ding R; Sun Y; Ma X
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Jun; 26(6):420-4. PubMed ID: 24912642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The influence of serum magnesium level on the prognosis of critically ill patients].
    Chen M; Sun R; Hu B
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 Mar; 27(3):213-7. PubMed ID: 25757972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunological benefit of higher dose N-acetyl cysteine following mechanical ventilation in critically ill patients.
    Najafi A; Mojtahedzadeh M; Ahmadi KH; Abdollahi M; Mousavi M; Chelkeba L; Najmeddin F; Ahmadi A
    Daru; 2014 Jul; 22(1):57. PubMed ID: 25027749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive value of four different scoring systems for septic patient's outcome: a retrospective analysis with 311 patients].
    Wang S; Li T; Li Y; Zhang J; Dai X
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Feb; 29(2):133-138. PubMed ID: 28625260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in plasma interleukin-33 concentration in sepsis and its correlation with seriousness of sepsis].
    Chang D; Jia J; Zang B
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 Feb; 27(2):138-42. PubMed ID: 25665614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers.
    Frantzeskaki FG; Karampi ES; Kottaridi C; Alepaki M; Routsi C; Tzanela M; Vassiliadi DA; Douka E; Tsaousi S; Gennimata V; Ilias I; Nikitas N; Armaganidis A; Karakitsos P; Papaevangelou V; Dimopoulou I
    J Crit Care; 2015 Apr; 30(2):276-81. PubMed ID: 25457114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients.
    Rosenbloom AJ; Linden PK; Dorrance A; Penkosky N; Cohen-Melamed MH; Pinsky MR
    Chest; 2005 Jun; 127(6):2139-50. PubMed ID: 15947332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.